ENCORE-MEDIA-GROUP
The IoT Tech Expo , Europe’s leading Internet of Things conference and exhibition welcomes Samsung , Vodafone and Ubuntu on board as platinum sponsors for their upcoming event in Berlin , Germany on the 13-14th June. The two day event will cover a range of industries including manufacturing, healthcare, logistics, transport, government, energy and automotive.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160420005975/en/
Over the 2 days there will be 5 dedicated conference tracks :
Topics include: connected car, smart home, customer experience, smart energy, connected home and monetisation
Speakers from: Tado, Shazam, Deutsche Telekom, Dixons Carphone, Ford, Honda and Jaguar Land Rover
Topics include: smart logistics, M2M, fleet management, digitalisation, smart manufacturing, predictive maintenance and telematics
Speakers from: DHL, Sandvik, Volvo, Konecranes, GE, Statoil, Postnord and TVH
Topics include: smart transportation, urban travel, carbon neutral, smart grids, sustainable cities, energy and big data
Speakers from: Continental, E.ON, City of Nice, City of Copenhagen, Bristol Is Open and GE
Topics include: data analytics, mass data collection, privacy challenges, big data modelling, and cyber security
Speakers from: Lufthansa Systems, European Parliament, Swiss Re, Orange and Konecranes
Topics include: robotics, development, connectivity, standards, investment, start-ups, wearables, AR, VR, future fashion, funding and healthcare
Speakers from: Husqvarna Group, Ubuntu, ETH Zurich, IDA Ireland, W3C, TUV, Samsung and Startupbootcamp
View the full speaker line-up, conference agendas and register your pass here: www.iottechexpo.com/germany
Super early bird prices end Friday 29th April so register now to save up to €295 on your delegate pass!
To learn more about the IoT Tech Expo and register your pass, visit the corresponding sites:
• IoT Tech Expo Central Europe : 13-14th June, Berlin Congress Center bcc, Germany
• IoT Tech Expo North America : 20-21st October, Santa Clara Convention Center, San Francisco, CA
• IoT Tech Expo Global : 23-24th January 2017, Olympia, London
For speaking, sponsorship and exhibitor enquiries please contact the team at enquiries@iottechexpo.com or call on +44 (0) 117 980 9023.
NOTES FOR EDITORS
About IoT Tech Expo
The IoT Tech Expo World Series (www.iottechexpo.com ) hosts top level content and discussion, introducing and exploring the latest innovations in the Internet of Things arena. It brings together key industries including Manufacturing, Transport, Health, Logistics, Government, Energy and Automotive.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420005975/en/
Contact:
IoT Tech Expo
Sarah Wheeler
Events Marketing & Conference
Executive
sarah@iottechexpo.com
+44
(0) 117 980 9023
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom